NGM Biopharmaceuticals Inc expected to post a loss of 36  cents a share - Earnings Preview

NGM Biopharmaceuticals

28/02/2022 11:48

* NGM Biopharmaceuticals Inc  NGM.OQ   NGM.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 2
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 2.2% increase in revenue to $20.196 million from
$19.77 million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NGM
Biopharmaceuticals
Inc is for a loss of 36 cents per share. For the same quarter
last year, the company reported a loss of 40 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $35​, about 56.7% above​ its last
closing price of $15.15. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.37       -0.35      -0.37     Missed  -5.7
 Jun. 30 2021  -0.34       -0.37      -0.48     Missed  -29.1
 Mar. 31 2021  -0.42       -0.42      -0.36     Beat    14​
 Dec. 31 2020  -0.51       -0.47      -0.40     Beat    15.1
 ​​Sep.        -0.38       -0.38      -0.43     Missed  -13.6
 30 2020                                                
 Jun. 30 2020  -0.30       -0.31      -0.38     Missed  -21.4​
 Mar. 31 2020  -0.26       -0.27      -0.28     Missed  -4.7
 Dec. 31 2019  -0.27       -0.27      -0.24     Beat    10.2
 This summary was machine generated February 28 at 11:48 GMT. 
All figures in US dollars  unless otherwise stated